Outsourced Pharma Capacity Update – Large Molecule Fall 2025

Abzena’s head of Cell Line Development, Dr Brett Verstak, from our Cambridge, UK Early Phase R&D site for Complex Biologics and Bioconjugates, presented at the Outsourced Pharma Capacity Update focused on Large Molecules on Oct. 7th, 2025.

This on-demand presentation showcases our newly expanded AbZelectPRO™ mammalian cell line development platform, designed to de-risk and streamline the development path for biopharma customers seeking a flexible, scalable, and rapid solution for IND and beyond.

Gain insight into:

• AbZelectPRO™ , AbZelectPRO™-KO , and AbZelectPRO™ -KO+ – mammalian CLD platforms enable the rapid progression from DNA to RCB in 10 weeks for therapeutic antibodies & difficult-to-express proteins
• Robust CHO-K1 & GS Knockout expression systems are combined with de-risked CLD workflows and next-gen 2G UNic® vector technology to offer enhanced productivity and high-quality titers up to 10g/L
• Backed by an extensive in-house analytical portfolio, which ensures an efficient, stable, & scalable production – simplifying the IND application process and delivering customers’ complex biologics successfully to the clinic

Watch the On-Demand Presentation

Abzena’s Cell Line Development Expertise
As a CDMO with over two decades of experience in CLD, Abzena has expertise in expressing biologics ranging from mAbs, antibody fragments, fusion proteins, and vaccines. Having developed hundreds of cell lines, we are here to help you accomplish your goals and help progress your program to its next target inflection point with greater success. Click here to learn more about our standalone and fully integrated cell line development offering.